The impact of various antihypertensive medications on vascular aging
E. N. Dudinskaya,
L. V. Matchekhina,
K. A. Eruslanova,
O. A. Dogotar,
L. P. Ryltseva,
N. Yu. Lyzlova,
N. A. Shchepin,
Yu. V. Kotovskaya https://doi.org/10.18705/1607-419X-2021-27-2-133-145
Abstract
The review summarizes the data of past two decades on the effect of hypertension on vascular aging and considers the effect of chronic inflammation and oxidative stress patterns on the remodeling of cardiovascular system. Clinical studies on the effect of various classes of antihypertensive drugs on age-associated parameters of vascular aging are discussed. These include endothelial dysfunction and arterial assessed by endothelium-dependent vasodilation, pulse wave velocity, augmentation index, cardiovascular index, thickness of the intima-media complex, and so on.
About the Authors
E. N. Dudinskaya
Pirogov Russian National Medical Research University
Russian Federation
Russian Federation
Ekaterina N. Dudinskaya, MD, PhD, Head, Laboratory of Agerelated Endocrine and Metabolic Diseases, Gerontology Research Centre
16 1-st Leonova street, Moscow, 129226 Russia
L. V. Matchekhina
Pirogov Russian National Medical Research University
Russian Federation
Russian Federation
Lubov V. Matchekhina, MD, PhD, Research Fellow, Laboratory of Age-related Endocrine and Metabolic Diseases, Gerontology Reseacrh Centre
Moscow
K. A. Eruslanova
Pirogov Russian National Medical Research University
Russian Federation
Russian Federation
Kseniya A. Eruslanova, MD, Junior Research Fellow, Laboratory of Cardiovascular Ageing, Gerontology Resaech Centre
Moscow
O. A. Dogotar
RUDN University
Russian Federation
Russian Federation
Olesia A. Dogotar, MD, PhD, Associate Professor, Medical Institute Simulation Training Center
Moscow
L. P. Ryltseva
RUDN University
Russian Federation
Russian Federation
Lidia P. Ryltseva, Student
Moscow
N. Yu. Lyzlova
RUDN University
Russian Federation
Russian Federation
Nataliya Y. Lyzlova, Student
Moscow
N. A. Shchepin
RUDN University
Russian Federation
Russian Federation
Nickolay A. Shchepin, Student
Moscow
Yu. V. Kotovskaya
Pirogov Russian National Medical Research University
Russian Federation
Russian Federation
Yuliya V. Kotovskaya, MD, PhD, DSc, Professor, Deputy Director, Gerontology Research Centre
Moscow
References
1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2
2. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. In Russian.
3. The Demographic Yearbook of Russia. Rosstat. M. 2019. 263 p. In Russian.
4. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol. 2010;25(4):394–398. doi:10.1097/hco.0b013e328338c109
5. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi:10.1016/j.jacc.2009.10.061
6. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–369. doi:10.1161/HYPERTENSIONAHA.110.167015
7. Strazhesko ID, Tkacheva ON, Akasheva DU, Dudinskaya EV, Agaltsov MV, Kruglikova AS et al. Correlations of different structural and functional characteristics of arterial wall with traditional cardiovascular risk factors in healthy people of different age. Part 2. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2016;12(3):244–252. In Russian.
8. Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S, Reference Values for Arterial Measurements Collaboration. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J. 2013;34(30):2368–2380. doi:10.1093/eurheartj/ehs380
9. Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116(6):1007–1021. doi:10.1161/CIRCRESAHA.116.303596
10. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005;45(6):1050–1055. doi:10.1161/01.HYP.0000164580.39991.3d
11. Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526. doi:10.1097/HJH.0b013e328361e4bd
12. Laslett LJ, Alagona P, Clark BA, Drozфda JP, Saldivar F, Wilson SR et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S 1–S 49. doi:10.1016/j.jacc.2012.11.002
13. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54(1):3–10. doi:10.1161/HYPERTENSIONAHA.109.129114
14. Mitchell GF. Arterial stiffness and wave reflection: biomarkers of cardiovascular risk. Artery Res. 2009;3(2):56–64. doi:10.1016/j.artres.2009.02.002
15. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(6):1239–1245. doi:10.1161/01.HYP.0000128420.01881.aa
16. Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51(14):1377–1383. doi:10.1016/j.jacc.2007.10.065
17. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001;59(5):1834–1841. doi:10.1046/j.1523-1755.2001.0590051834.x
18. Agabiti-Rosei E, Mancia G, O’Rourke MF, Roman MJ, Safar ME, Smulyan H et al. Central blood pressure measurements and antihypertensive therapy a consensus document. Hypertension. 2007;50(1):154–160. doi:10.1161/HYPERTENSIONAHA.107.090068
19. Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci (Lond). 2010;119(4):151–161. doi:10.1042/CS20090544
20. Falkner B. Hypertension in children and adolescents: epidemiology and natural history. Pediatr Nephrol. 2010;25(7):1219–1224. doi:10.1007/s00467-009-1200-3
21. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Seidell JC, Stehouwer CD. Current and adolescent body fatness and fat distribution: relationships with carotid intima-media thickness and large artery stiffness at the age of 36 years. J Hypertens. 2004;22(1):145–155. doi:10.1097/00004872-200401000-00024
22. Petersen KS, Blanch N, Keogh JB, Clifton PM. Effect of weight loss on pulse wave velocity: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015;35(1):243–252. doi:10.1161/ATVBAHA.114.304798
23. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281–1286. doi:10.1161/01.HYP.0000070956.57418.22
24. Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16(5):309–321. doi:10.1007/s40256-016-0173-4.
25. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007;21(6):423–429. doi:10.1007/s10557-007-6068-5
26. Sirenko JuN, Rekovec OL, Kushnir SN, Torbas E. Comparative efficiency of enalapril and perindopril in terms of the effect on central blood pressure and elastic properties of arteries in patients with mild to moderate hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2016;2(46):101–112. In Russian.
27. Nedogoda SV, Palashkin RV, Ledjaeva AA, Chumachyok EV, Smirnova VO, Khripaeva VYu. Preventing early vascular aging in obese patients who are receiving angiotensin-converting enzyme inhibitors. Doсtor.Ru. 2016;11(128):5–9. In Russian.
28. Strazhesko ID. Age-associated changes in the arterial wall: relationship with hormonal-metabolic status and telomere biology. [PhD thesis]. M., 2019. URL: https://www.dissercat.com/content/vozrast-assotsiirovannye-izmeneniya-arterialnoi-stenki-vzaimosvyaz-s-gormonalno-metaboliches In Russian.
29. Tropeano AI, Boutouyrie P, Pannier B,Joannides R, Balkestein E, Katsahian S et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–86. doi:10.1161/01.HYP.0000224283.76347.8c
30. Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, Winter S, Ligthart JMR et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007;100(2):159–163. doi:10.1016/j.amjcard.2007.02.073
31. Bruining N, de Winter S, Roelandt JR, Rodriguez-Granillo GA, Heller I, van Domburg RT et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009;20(6):409–414. doi:10.1097/MCA.0b013e32832fa9b8
32. Bots ML, Remme WJ, Lüscher TF, Fox KM, Bertrand M, Ferrari R et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther. 2007;21(4):269–279. doi:10.1007/s10557-007-6041-3
33. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10.1016/j.cardiores.2006.10.021
34. You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M et al. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension. 2008;51(6):1537–1544. doi:10.1161/HYPERTENSIONAHA.107.109066
35. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35(1):60–66. doi:10.1016/s0735-1097(99)00537-9
36. De Gennaro Colonna V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol. 2002;450(1):61–6. doi:10.1016/S0014-2999(02)02046-0
37. Leonova MV, Demidova MA, Tarasov AV, Belousov Ju B. Antihypertensive, organoprotective and metabolic efficacy of Spirapril in hypertensive patients. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2005;1(2):4–8. In Russian.
38. Olejnikov VJe, Matrosova IB, Tomashevskaja JuA, Gerasimova AS. The impact of ACE inhibitor Quadropril on structural and functional properties of vascular wall in metabolic syndrome and essential hypertension. Russian Journal of Cardiology. 2006;58(2):36–41. In Russian.
39. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circ Res. 2018;123(7):849–867. doi:10.1161/CIRCRESAHA.118.311378
40. Podzolkov VI, Pisarev MV, Zateyshchikova DA. Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities. Russian Journal of Cardiology. 2018;(11):89–95. doi:10.15829/1560-4071-2018-11-89-95. In Russian.
41. Nedogoda SV. PPAR-γ-activation is a key benefit of telmisartan and its combinations. Atmosphere. Novosti Kardiologii = Cardiology news. 2016;1. In Russian.
42. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial [published correction appears in Lancet. 2008;372(9647):1384]. Lancet. 2008;372(9644):1174–1183. doi:10.1016/S0140-6736(08)61242-8
43. Flavahan S, Chang F, Flavahan NA. Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries. Am J Physiol Heart Circ Physiol. 2016;311(3): H849-H854. doi:10.1152/ajpheart.00422.2016
44. Yakovleva MV, Pribylov SA, Pribylova NN. Effect of ACE inhibitors, sartans and surgical revascularization on the rigidity of the vascular wall in patients with coronary heart disease in combination with chronic kidney disease. Kyrskiy Nauchno-prakticheskiy Vestnik “Chelovek I ego Zdorovie” = Kursk Scientific and Practical Bulletin “Man and his health”. 2019;(3):12–19. doi:10.21626/vestnik/2019–3/02. In Russian.
45. Janić M, Lunder M, Novaković S, Škerl P, Šabovič M. Expression of longevity genes induced by a low-dose fluvastatin and valsartan combination with the potential to prevent/treat “Aging-Related Disorders”. Int J Mol Sci. 2019;20(8):1844. doi:10.3390/ijms20081844
46. Shan H, Zhang S, Li X, Yu K, Zhao X, Chen X et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014;18(6):1071–1080. doi:10.1111/jcmm.12251
47. Lunder M, Janic M, Sabovic M. Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Prev Cardiol. 2012;19(6):1243–1249. doi:10.1177/1741826711423104
48. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104(5):511–514. doi:10.1161/hc3001.094207
49. Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111(5): 309–316. doi:10.1111/j.1742-7843.2012.00911.x
50. Pristrom AM, Gaishun EI. Effect of β-blockers on the extensibility and elasticity of the common carotid artery in patients with chronic ischemic heart disease who underwent intracoronary stenting. Meditsinskiye Novosti = Medical News. 2012;6. In Russian.
51. Kelly AS, Gonzalez-Campoy JM, Rudser KD, Katz H, Metzig AM, Thalin M et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich). 2012;14(2):85–91. doi:10.1111/j.1751-7176.2011.00569.x
52. Oleynikov VE, Matrosova IB, Tomashevskaya YA, Gusakovskaya LI, Melnikova EA. Effect of metoprolol therapy on the arterial stiffness. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2011;7(6): 685–689. In Russian.
53. Majidinia M, Rasmi Y, Khadem Ansari MH, Seyed-Mohammadzad M, Saboory E, Shirpoor A. Metoprolol improves endothelial function in patients with cardiac syndrome X. Iran J Pharm Res. 2016;15(3):561–566.
54. Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure. J Am Heart Assoc. 2017;6(11):e007437. doi:10.1161/JAHA.117.007437
55. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103(13):1721–1726. doi:10.1161/01.cir.103.13.1721
56. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33(2):572–577. doi:10.1161/hs0202.102332
57. Matsubara M, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis. 2005;178(1):57–66. doi:10.1016/j.atherosclerosis.2004.08.020
58. Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function — a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79. doi:10.1186/1475-2840-10-79
59. Yasu T, Kobayashi M, Mutoh A, Yamakawa K, Momomura S, Ueda S. Dihydropyridine calcium channel blockers inhibit non-esterified-fatty-acid-induced endothelial and rheological dysfunction. Clin Sci (Lond). 2013;125(5):247–255. doi:10.1042/CS20120311
60. Okamura T, Tawa M, Geddawy A, Shimosato T, Iwasaki H, Shintaku H et al. Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci. 2014;124(1):76–85. doi:10.1254/jphs.13178fp
61. Zhou MS, Tian R, Jaimes EA, Raij L. Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. Am J Hypertens. 2014;27(6):873–880. doi:10.1093/ajh/hpt272
62. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1
63. Golovanova ED. Vascular remodeling and heart rate variability in pharmacotherapy of arterial hypertension by various means. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2008;4(1):62–66. doi:10.20996/1819-6446-2008-4-1-62–66. In Russian.
64. Kobalava ZhD, Kotovskaya YuV, Markova MA, Villevalde SV. High systolic pressure: emphasis on the elastic properties of arteries. KBTiP. 2006;5(6):10–16. In Russian.
Review
For citations:
Dudinskaya E.N., Matchekhina L.V., Eruslanova K.A., Dogotar O.A., Ryltseva L.P., Lyzlova N.Yu., Shchepin N.A., Kotovskaya Yu.V. The impact of various antihypertensive medications on vascular aging. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(2):133-145. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-2-133-145
Views:
1016
Email this article 